Palisade Capital Management LLC Incyte Corp Transaction History

Palisade Capital Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 13, 2019	SELL	$63.56 - $88.17 $218,773 - $303,481	-3,442 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$61.75 - $74.23 $5,681 - $6,829	92 Added 2.75%	3,442 $238,000
Q2 2018 Aug 13, 2018	BUY	$60.85 - $83.98 $30,425 - $41,990	500 Added 17.54%	3,350 $224,000
Q1 2018 May 09, 2018	BUY	$83.06 - $100.98 $20,765 - $25,245	250 Added 9.62%	2,850 $237,000
Q4 2017 Feb 09, 2018	BUY	$93.56 - $116.6 $46,780 - $58,300	500 Added 23.81%	2,600 $246,000
Q3 2017 Oct 31, 2017	BUY	$109.15 - $138.27 $229,215 - $290,367	2,100	2,100 $245,000

649

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Palisade Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Palisade Capital Management LLC with notifications on news.